ASCO 2017: Next Generation of ALK TKI Inhibitors for Treatment of Advanced ALK-positive NSCLC

Speaker: Alice Shaw

Alice Shaw reports on two studies' results presented on 2nd and 3rd generation ALK inhibitors in front- and further lines of treatment for ALK positive non-small cell lung cancer patients.

Alice Shaw reports on two studies' results presented on 2nd and 3rd generation ALK inhibitors in front- and further lines of treatment for ALK positive non-small cell lung cancer patients.

Abstracts as referenced in the ASCO 2017 programme

  • LBA9008: Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.
  • 9006:  Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) with one or more prior ALK Tyrosine kinase inhibitor (TKI): A phase I/II study.